Interviews

Breaking Through the Investment Gap: Mark Andrews Discusses British Patient Capital's Life Sciences Fund

by Andrii Buvailo, PhD  (contributor )   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

In this interview, we speak with Mark Andrews, Investment Director, Life Sciences, Funds at British Patient Capital, the largest domestic investor into UK venture capital opportunities, including pharmaceutical industry and biotech. Mark sheds light on the investment strategy of British Patient Capital, the specific biotech and healthcare sectors that they prioritise, the eligibility criteria for prospective startups or projects, and the major shifts that can be anticipated in the UK's life science industry in the coming years.

#advertisement
AI in Drug Discovery Report 2025

Continue reading

This content available exclusively for BPT Mebmers

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email